About this episode
Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash.
In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite. It capped its discounts and built its own labs and supply chain, and it treats fast delivery as a minor add-on.
In this episode, we unpack why patience beats blitzscaling in Indian healthcare and what 1mg means when it calls healthcare longitudinal.
Take The Great Rewiring survey here
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
Get every episode summarized
Each time Daybreak publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Daybreak
This week in AI: activist robots, doom-laden researchers — so who's the good guy...
Daybreak
India has more tourists than ever. So why is tourism in trouble?
Daybreak
The Government sold Air India to escape its problems. The fix is to buy back in
Daybreak
Nykaa cracked fashion at last. Myntra sees no reason to panic
Daybreak